(4S)-3-[(5R)-5-(4-Fluorophenyl)-5-Hydroxypentanoyl]-4-pheny-1,3-oxzolidin-2-One

(4S)-3-[(5R)-5-(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4-PHENYL-1,3-OXAZOLIDIN-2-ONE;(4S)-3-[(5S)-5-(4-Fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one;(4S)-4-Phenyl-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]Chemicalbook-1,3-oxazolidin-2-one;(4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxo-pentyl]-4-phenyl-2-Oxazolidinone;EzetiMibeInterMediates;3-[(5S)-5-(4-fluorophenyl)-5-hydroxy-1-oxopentyl]-4-phenyl-,(4S)-2-Oxazolidinone;EzetimibeINTA;ZT-5

Overview Ezetimibe is a drug jointly developed by Schering-Plough and Merck for the treatment of hyperlipidemia. It was approved by the US FDA in 2002 and is marketed under the trade name Zetia. Its chemical name is: 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl) -2-propionolactam. Hyperlipidemia is an important risk factor for the occurrence of cardiovascular diseases such as atherosclerosis. Lowering the total cholesterol level in plasma can reduce the risk of cardiovascular diseases Chemicalbook. Use (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxyvaleryl]-4-phenyl-1,3-oxazacyclopentan-2-one as the base Intermediates for the preparation of zetimibe. Ezetimibe's current clinical drugs for the treatment of hyperlipidemia mainly include cholesterol synthesis inhibitors, phenoxy acids, and bile acid sequestrants. Ezetimibe selectively inhibits the absorption of cholesterol from the biliary tract and food by acting on the brush border of small intestinal cells without affecting the absorption of fat-soluble vitamins, triglycerides, and bile acids. Usage Ezetimibe intermediate